Shanghai, China | 13rd May, 2025 — Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company devoted to the discovery and development of nanobody therapeutics, announced today that it has been invited to present at the Respiratory Innovation Summit (RIS) and the American Thoracic Society (ATS) International Conference Session ”Winning the Biologic Battle in Asthma and COPD”, taking place in San Francisco, California, from May 16 to 21.

At these prestigious meetings, Novamab will present two scientific posters featuring the first-in-class Phase IIa proof-of-concept clinical data for LQ036, the innovative inhaled biologic targeting IL-4Rα. The data will provide an in-depth evaluation of safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy in patients with asthma. This presentation marks a significant milestone in Novamab’s mission to advance next-generation inhaled biologic therapies for respiratory diseases.

About ATS 2025

The American Thoracic Society (ATS) Annual Meeting is the world's largest and most influential professional academic conference in the respiratory field. Each year, it attracts over 14,000 participants from around the globe to share the latest advancements in respiratory medicine, critical care, sleep medicine, and groundbreaking research. Many internationally significant scientific discoveries and research outcomes are first unveiled at the ATS Annual Meeting.

Founded in 1905, the American Thoracic Society (ATS) stands as the world’s most authoritative respiratory academic organization, with a membership exceeding 16,000 professionals. ATS is committed to improving global health by advancing research, patient care, and public health in pulmonary diseases, critical care medicine, sleep medicine, and related disciplines.

Shanghai Novamab Biopharmaceuticals Co., Ltd. (Novamab), located in the Shanghai International Medical Zone (Pudong New Area, Shanghai), is a clinical-stage company dedicated to developing innovative VHH antibody therapeutics targeting multi-billion-dollar autoimmune and inflammatory disease markets. Our mission is to create life-transforming therapies for patients through pioneering heavy-chain antibody (VHH) drug development, with a focus on enhancing therapeutic efficacy and treatment convenience.

Novamab currently employs approximately 65 full-time staff. As a global pioneer in VHH antibody development, we maintain a highly differentiated innovative product pipeline targeting high-potential markets such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). Our focus lies in creating unique treatment solutions to address significant clinical challenges. Our most advanced program is an inhaled IL-4Rα candidate currently in Phase II clinical trials, while our inhaled TSLP program is poised to initiate a Phase Ib proof-of-concept study. Additionally, we are actively developing several bispecific and oral VHH antibody candidates designed to treat inflammatory bowel disease (IBD).